Corcept Therapeutics (CORT)Chief Business Officer sold ~$225K

~$225K

Approx. value · 3,185 sh @ $70.77

13K

Holds after · shares reported

Traded

Jun 16, 2025

Filed

Jun 18, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 1, 2025Insider · 2 peopleInsiders: 2 sales (~$1.6M)
2. May 2, 2025Insider · 2 peopleInsiders: 4 sales (~$4.8M)
3. May 6, 2025InsiderOfficer sold ~$525K of CORT shares in the open market
4. May 12, 2025Insider · 1 personInsiders: 2 sales (~$159K)
5. May 16, 2025Insider · 2 peopleInsiders: 3 sales (~$4.4M)
6. May 20, 2025InsiderOfficer sold ~$173K of CORT shares in the open market
7. Jun 2, 2025Insider · 3 peopleInsiders: 14 sales (~$5.3M)
8. Jun 10, 2025Insider · 2 peopleInsiders: 3 sales (~$1.6M)
9. Jun 16, 2025 · this disclosureInsiderOfficer sold ~$225K of CORT shares in the open market

What came next

1. Jul 1, 2025Insider · 3 peopleInsiders: 3 sales (~$30K)
2. Jul 10, 2025InsiderDirector sold ~$156K of CORT shares in the open market
3. Jul 17, 2025Insider · 4 peopleInsiders: 4 sales (~$969K)
4. Jul 18, 2025Insider · 3 peopleInsiders: 3 sales (~$86K)
5. Aug 1, 2025Insider · 3 peopleInsiders: 7 sales (~$5.5M)
6. Aug 5, 2025InsiderOfficer sold ~$1K of CORT shares in the open market
7. Aug 8, 2025InsiderOfficer sold ~$2.51M of CORT shares in the open market
8. Aug 11, 2025InsiderDirector sold ~$159K of CORT shares in the open market
9. Aug 22, 2025InsiderOfficer sold ~$166K of CORT shares in the open market
10. Sep 2, 2025Insider · 4 peopleInsiders: 8 sales (~$6.0M)
11. Sep 10, 2025InsiderDirector sold ~$159K of CORT shares in the open market
12. Oct 6, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 6, 2025, Gillian Cannon, Ph.D., notified the Board of Directors (the “Board”) of Corcept Therapeutics Incorporated (the “Company”) of her resignation from the Board, effective as of October 10, 2025 (the “Effective Date”).”
13. Oct 7, 2025InsiderOfficer sold ~$1.8M of CORT shares in the open market
14. Oct 10, 2025Company filing · Form 8-K · Agreement endedEnded an important agreement

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Corcept Therapeutics

For Corcept Therapeutics, OQRO holds 64 insider filings (SEC Form 4 or Form 144) and 5 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CORT page.

Other recent filings by Gary Charles Robb, Chief Business Officer

• SEC Form 4 at Corcept Therapeutics (CORT)Aug 19, 2026
• SEC Form 4 at Corcept Therapeutics (CORT)Aug 26, 2025
• SEC Form 4 at Corcept Therapeutics (CORT)May 22, 2025
• SEC Form 4 at Corcept Therapeutics (CORT)Jan 7, 2025
• SEC Form 4 at Corcept Therapeutics (CORT)Nov 26, 2024

The full history of Gary Charles Robb, Chief Business Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Corcept Therapeutics

• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026

Everything OQRO holds on this company is on its CORT page.